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Background: Atrioventricular accessory pathways (APs) in dogs have been reported rarely. Data
regarding clinical presentation and long-term outcome after radiofrequency catheter ablation
(RFCA) are limited.
Hypothesis/Objectives: To study clinical features, electrophysiologic characteristics, and out-
come of RFCA in dogs with APs.
Animals: Eighty-nine dogs presented consecutively for RFCA of APs.
Methods: Case series.
Results: Labrador retrievers (47.2% of dogs) and male dogs (67.4% of dogs) were most commonly
affected. Labrador retrievers were more likely to be male than non-Labrador breeds (P = .043).
Clinical signs were nonspecific and most commonly included lethargy and gastrointestinal signs.
Concealed APs were more prevalent in Labrador retrievers than other breeds (P = .001). Right-
sided APs (91.7%) predominated over left-sided (8.3%). Tachycardia-induced cardiomyopathy
(TICM) occurred in 46.1% of dogs, with complete resolution or substantial improvement noted on
one-month postablation echocardiograms. Radiofrequency catheter ablation successfully elimi-
nated AP conduction long term in 98.8% of dogs in which it was performed. Complications
occurred in 5/89 dogs. Recurrence in 3 dogs was eliminated long term with a second procedure.
Clinical Importance/Conclusions: Accessory pathways are challenging to recognize in dogs
because of nonspecific clinical signs, frequency of concealed APs that show no evidence of their
presence during sinus rhythm, and intermittent occurrence of tachyarrhythmias resulting from
APs. Tachycardia-induced cardiomyopathy commonly occurs with AP-mediated tachycardias
and should be considered in any dog presenting with a dilated cardiomyopathic phenotype
because of its good long-term prognosis with rhythm control. Radiofrequency catheter ablation
is a highly effective method for eliminating AP conduction and providing long-term resolution.
KEYWORDS
accessory pathway, congestive heart failure, orthodromic atrioventricular reciprocating
tachycardia, tachycardia, tachycardia-induced cardiomyopathy, ventricular preexcitation
Abbreviations: AF, atrial fibrillation; AP, atrioventricular accessory pathway; APC, atrial premature complex; AV, atrioventricular; CHF, congestive heart failure; CS,
coronary sinus; EP, electrophysiology or electrophysiologic; EPS, electrophysiologic study; HB, His Bundle; HRA, high right atrium; LA:Ao, left atrium to aortic ratio;
LV, left ventricle or left ventricular; LVESVI, left ventricular end-systolic volume index; LVFS, left ventricular fractional shortening; LVIDdN, normalized left ventricular
internal diameter at end-diastole; LVIDsN, normalized left ventricular internal diameter at end-systole; OAVRT, orthodromic atrioventricular reciprocating tachycardia;
RF, radiofrequency energy; RFCA, radiofrequency catheter ablation; RV, right ventricle or right ventricular; RVA, right ventricular apex; TICM, tachycardia-induced
cardiomyopathy; VA, ventricular-to-atrial; VF, ventricular fibrillation; VPC, ventricular premature complex; VPE, ventricular preexcitation; VT, ventricular tachycardia
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1 | INTRODUCTION
Atrioventricular accessory pathways (APs) are anomalous bypass
tracts typically composed of working myocardial cells.1 Such APs can
form the retrograde limb of a macroreentrant circuit using the atrio-
ventricular (AV) node as the antegrade limb, resulting in a regular, nar-
row complex tachyarrhythmia known as orthodromic atrioventricular
reciprocating tachycardia (OAVRT). If the AP is capable of antegrade
conduction, an ECG recorded during sinus rhythm may demonstrate
ventricular preexcitation (VPE), characterized by a short PR interval
and slurred upstroke to the QRS, known as a delta wave. The degree
of VPE depends upon (1) AV nodal and His-Purkinje conduction time,
(2) conduction time of the sinus impulse to the AP, and (3) conduction
time through the AP.2,3 Ventricular preexcitation may be present con-
sistently in sinus rhythm (manifest APs) or only intermittently. Wolff-
Parkinson-White syndrome (WPW) is the combination of VPE during
sinus rhythm and periods of symptomatic tachyarrhythmia. An AP
only capable of retrograde conduction is known as a concealed AP,
and the ECG during sinus rhythm will have a normal PR interval and
QRS complex.
Rarely, an AP capable of antegrade conduction may participate as
the antegrade limb of a macroreentrant tachycardia circuit, while the
AV node forms the retrograde limb. This results in a wide complex
tachyarrhythmia known as antidromic AV reciprocating tachycardia. A
major risk for sudden cardiac death occurs when a patient having an
AP with rapid antegrade conduction properties develops atrial fibrilla-
tion (AF). Atrial impulses can be rapidly conducted over the antegrade
AP, resulting in ventricular fibrillation (VF).4
Tachycardia-induced cardiomyopathy (TICM) can result from
frequent or sustained tachyarrhythmias, including OAVRT. It is
defined as myocardial dysfunction caused by a rapid ventricular rate
that is completely or partially reversible after normalization of the
heart rate.5,6 Our knowledge of APs and TICM in dogs currently is
limited. Single case reports and small case series have been
reported.7–13
Radiofrequency catheter ablation (RFCA) is a minimally invasive
technique targeting a tachyarrhythmic focus or reentrant circuit
with radiofrequency energy to permanently disrupt that tachyar-
rhythmia.14 This procedure has been reported in a small number of
dogs with APs.8–13 Study goals were (1) describe the clinical, elec-
trocardiographic, echocardiographic, and electrophysiologic find-
ings in a large consecutive series of dogs with APs and (2) report
RFCA procedural and long-term outcomes, with assessment of
potential curative properties for RFCA in a clinical population
of dogs.
2 | MATERIALS AND METHODS
2.1 | Animals
Eighty-nine dogs were referred to the principal author for electro-
physiologic study (EPS) and RFCA of APs between September 1999
and February, 2017. Data from clinical history, CBC, serum biochemi-
cal profiles, echocardiograms, electrocardiograms, Holter monitors,
and thoracic radiographs were collected by consultation with owners
and referring cardiologists or internists.
Complete echocardiographic evaluation (2D, M-mode, Doppler)
was performed by a single cardiologist (KW) at the time of presenta-
tion for EPS. Measurements of LV systolic function included fractional
shortening (LVFS), normalized LV internal diameter at end-systole
(LVIDsN), ejection fraction (LVEF), and LV end-systolic volume index
(LVESVI) using the modified Simpson’s formula in the left parasternal
4-chamber and 2-chamber views. Left ventricular systolic dysfunction
was defined as having at least 3 of these 4 measurements outside of
the reference ranges (LVFS <25%, LVIDsN > 1.14, LVEF <50%,
LVESVI > 35 ml/M2).15,16 Normalized left ventricular internal diameter
at end-diastole (LVIDdN) and 2D right parasternal short-axis LA-to-
aortic (LA:Ao) ratio were evaluated, with dilatation defined as LVIDdN
> 1.73 and 2D LA:Ao > 1.5.15,17,18 The presence and severity of valvu-
lar regurgitation and concurrent congenital or acquired cardiac defects
were recorded.
Twelve-lead electrocardiograms were obtained on the day of pre-
sentation, followed by telemetric monitoring until the time of dis-
charge. Analyzed data included presence or absence of VPE (on any
ECG), tachycardia cycle length, RP0 interval during OAVRT, presence
or absence of P0 waves in the ST segment/T wave following at least
some sinus complexes, other arrhythmias present before ablation, and
antiarrhythmic drugs used.
2.2 | Electrophysiologic study and radiofrequency
catheter ablation
Orally administered antiarrhythmic drugs were discontinued for
5 half-lives prior to EPS. Some dogs were hemodynamically unstable
with their tachycardia, however, and required an IV injection of diltia-
zem or lidocaine to convert them to sinus rhythm within 24 hours
before the procedure. Dogs were premedicated with butorphanol and
midazolam, followed by anesthetic induction with etomidate, and
maintenance with the lowest concentration of isoflurane needed to
maintain a stable plane of anesthesia. Multielectrode catheters
(Boston Scientific quadripolar fixed curve and decapolar fixed and
steerable curve diagnostic electrophysiology catheters) were
advanced through percutaneously placed catheter introducers in both
femoral and external jugular veins to the right ventricular apex (RVA),
high right atrium (HRA), His bundle region (HB), and coronary sinus
(CS; Figure 1).14 Electrical stimuli were delivered at twice diastolic
threshold from a programmable stimulator (Bloom DTU-215 Program-
mable Cardiac Stimulator) to the distal electrodes of first the HRA and
then RVA. Trains of 8 S1 extrastimuli followed by a progressively
more premature single S2 extrastimulus were used to determine
effective refractory periods, whereas incrementally faster trains of
8 extrastimuli were used to determine fastest 1-to-1 conduction prop-
erties of the AP and normal conduction system in antegrade and ret-
rograde directions, respectively.19 High right atrial or RVA extrastimuli
were used to induce the clinical tachyarrhythmia and any other induc-
ible rhythms. An AP was confirmed using ≥1 of these criteria: (1) ven-
tricular activation occurring before the HB potential (VPE) during
sinus rhythm or atrial pacing; (2) eccentric atrial activation during ven-
tricular pacing and narrow complex tachyarrhythmia; (3) rapid,
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nondecremental VA conduction during decremental RV pacing with
identical retrograde atrial activation at all cycle lengths (particularly
important if concentric retrograde atrial activation occurs).20–22 Rare
APs exhibit slow, decremental retrograde conduction properties. To
distinguish OAVRT from AV nodal reentry or atrial tachycardia with
1:1 AV nodal conduction, AP participation in the tachycardia circuit
was confirmed by advancing (or delaying in the case of a decremen-
tally conducting AP) the identical retrograde atrial activation sequence
or terminating the tachycardia without subsequent atrial activation
after introduction of a single RV extrastimulus into the tachycardia
during His bundle refractoriness.20–22 Continuation of the tachycardia
despite AV block or earliest atrial activation distant from the AV annuli
excluded OAVRT and strongly supported atrial tachycardia. A fixed
VA (and RP0) interval during tachycardia and tachycardia termination
by a premature RV stimulus that does not conduct to the atrium were
seen with OAVRT, not atrial tachycardia.20–22
Once the baseline EP study was completed, the HRA catheter
was replaced by a 6-7F deflectable quadripolar ablation catheter
(Blazer II Temperature Ablation Catheter) positioned along the tri-
cuspid annulus (Figure 2A). If a left-sided accessory pathway was
present, a separate 7F catheter introducer was inserted into the
right femoral artery. The ablation catheter was advanced to the
mitral annulus by prolapsing it across the aortic valve (Figure 2B).
Detailed AP mapping and ablation were performed through the dis-
tal electrode bipole of the ablation catheter. The site of earliest ret-
rograde atrial activation during RVA pacing and OAVRT was used to
identify the atrial insertion site of the AP, whereas the earliest ven-
tricular activation during sinus rhythm or HRA pacing identified the
ventricular insertion site in manifest APs. An AP potential, which is a
discrete, sharp, low-amplitude signal between the ventricular and
atrial electrograms for retrograde APs or atrial and ventricular elec-
trograms for antegrade APs, also was sought in the the distal abla-
tion dipole recording before RF delivery.20,21,23–25 Most commonly,
the atrial insertion of AP was targeted for ablation during RV pacing.
In some cases with manifest preexcitation, the ventricular AP inser-
tion was targeted during preexcited sinus rhythm. The distal elec-
trode pair on the mapping catheter was coupled to a temperature-
controlled cardiac radiofrequency (RF) ablation unit (EPT 1000TC
Cardiac Ablation Unit). Temperature modulated mode was used for
all ablations. The RF generator was set to 60C-65C with a maximal
delivered power of 50 W for APs not located in the midseptal or
FIGURE 2 A, Left anterior oblique fluoroscopic view of a right
posteroseptal accessory pathway ablation. ABL: ablation catheter
at the ninth electrode of the CS catheter, which was located at the
coronary sinus os. All multielectrode catheter poles are labeled by
convention in numerical order starting at the distal (tip) electrode.
CS, coronary sinus decapolar catheter; His, decapolar catheter with
the tip electrodes located at the His bundle region. RV, quadripolar
catheter located in the right ventricle. B, Left anterior oblique
fluoroscopic view of a left anterior accessory pathway ablation.
ABL, ablation catheter that has been prolapsed retrograde across
the aortic valve and is deflected under the septal mitral valve
leaflet. CS, coronary sinus decapolar catheter. His, decapolar
catheter with the tip electrodes originally located at the His bundle
region; however, it had flipped away from the septum at the
time of this image. RV, quadripolar catheter located in the right
ventricle
FIGURE 1 A 30 left anterior oblique fluoroscopic view of
multielectrode catheter positioning for the initial EP study. HRA, high
right atrium; HB, His bundle region; CS, coronary sinus; RVA, right
ventricular apex. All multielectrode catheter poles are labeled by
convention in numerical order starting at the distal (tip) electrode
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anteroparaseptal regions. For those pathways near the normal con-
duction system, the temperature was decreased to 40C and maxi-
mal power decreased to 20 watts. If AP conduction was not
abolished within 8 seconds, RF delivery was discontinued and fine
mapping continued. When AP conduction terminated within 8 sec-
onds of the start of RF delivery, energy delivery was continued for
60 seconds. Except for the first 3 dogs, EP testing continued for
1 hour to ensure AP conduction did not recur.
Recorded EP data included antegrade and retrograde AP proper-
ties (fastest 1:1 conduction cycle length, effective refractory period,
stimulus-atrial interval during RVA pacing, VA interval during
OAVRT), AP location, time to AP block during RF delivery, and com-
plications encountered. Accessory pathway location was defined
based on the left anterior oblique view as left or right free wall or
septal/paraseptal. The free wall regions were further divided into
lateral, anterolateral, and posterolateral. The septal/paraseptal
regions were further divided into anteroparaseptal, midseptal, and
posteroparaseptal.11,26
2.3 | Follow-up
Each dog was monitored in the intensive care unit with telemetry for
at least 16 hours after the procedure before discharge. One to
2 months after ablation, 24-hour Holter monitoring was performed in
the dog’s home environment. An echocardiogram also was to be per-
formed by the referring cardiologist at this time.
Owners were contacted annually thereafter to assess patient sta-
tus. Long-term outcome and survival were assessed by identifying the
date and cause of death by contacting owners, referring cardiologists,
and family veterinarians. Cause of death was classified as cardiac (fur-
ther divided into whether deaths were associated with APs) or
noncardiac.
2.4 | Statistical analysis
Statistical analyses were performed using commercially available sta-
tistics software programs (Stata IC/13.1, StataCorp LP, College Sta-
tion, TX and StatXact, Cytel Software Corporation, Cambridge, MA).
Continuous variables were expressed as median (interquartile range)
for non-normally distributed variables or mean (standard deviation)
for normally distributed variables. Descriptive statistics were used for
demographic and categorical clinical data, expressed as number of
dogs displaying the variable of interest out of total number of dogs
that possibly could display that variable.
Least-squares linear regression was used for analyses between
2 continuous variables. Analyses between variables with 2 categories
were performed using logistic regression with robust variance estima-
tion to account for clustering of observations, whereas analyses of ≥3
categories used Kruskal–Wallis tests. A Mann–Whitney test was used
to compare fastest HRA pacing cycle length exhibiting 1:1 antegrade
conduction over the AP between intermittent and manifest preexcita-
tion groups. Analyses between pre- and post-RFCA echocardiographic
variables were done with Wilcoxon signed-rank tests. P values <.05
were considered statistically significant.
3 | RESULTS
3.1 | Signalment
Twenty-three different breeds were affected (Table 1). The most com-
mon breed was the Labrador Retriever (42/89, 47.2%), followed by
Golden Retrievers (7/89, 7.9%), Boxers (5/89, 5.6%), and English Bull-
dogs (4/89, 4.5%). Sixty of the 89 dogs (67.4%) were males. Affected
Labradors were significantly more likely to be male (33/42) than non-
TABLE 1 Clinical characteristics of 89 dogs with accessory
atrioventricular pathways
BREED No. of cases
Labrador Retriever 42
Golden Retriever 7
Boxer 5
Mixed breed 5
English Bulldog 4
Bernese Mountain Dog 3
German Shepherd Dog 2
Australian Shepherd 2
American Staffordshire Terrier 2
Beagle 2
Doberman 2
German Shorthaired Pointer 2
Alaskan Malamute 1
French Bulldog 1
American Bulldog 1
English Springer Spaniel 1
Weimaraner 1
Bassett Hound 1
Boerbel Mastiff 1
Boston Terrier 1
Deutsch Langerhaar 1
Pembroke Welsh Corgi 1
Border Collie 1
Sex No. of cases
Male 19
Male Castrated 41
Female 10
Female Spayed 19
Clinical signs noted by owner No. of cases
Intermittent lethargy/weakness 62
Hyporexia 47
Vomiting 33
Head bobbing/body or thorax bobbing 27
Labored breathing 19
Syncope/collapse 13
Seeks owner 8
Abdominal distention 8
Diarrhea 6
Coughing 5
Marked weight loss/cachexia 3
Reclusive 1
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Labrador breeds (27/47; P = .043). Median age at the time of presen-
tation was 2.3 years (range, 0.33-9.7 years), with no difference
between Labrador Retrievers and other breeds (P = .429). Median
time from diagnosis of VPE or a narrow complex tachycardia to pre-
sentation for ablation was 4 months (range, 0.5 months to 7.8 years).
3.2 | Clinical presentation
Presenting clinical signs are shown in Table 1. The most common sign
was intermittent lethargy or weakness (62/89, 69.7%), followed by
hyporexia (47/89, 52.8%) and vomiting (33/89, 37%). Three dogs
(3.3%) had marked weight loss or cachexia. Head bobbing or chest
pulsing was reported in 27/89 (30.3%). Syncope occurred in 13/89
(14.6%) and resuscitated cardiac arrest before referral in 2/89 (2.2%).
Documented CHF occurred in 34/89 dogs (38.2%). Of these,
14 (15.7%) exhibited left-sided CHF only, 11 (12.4%) right-sided CHF
only, and 9 (10.1%) biventricular CHF. No relationship was found
between presence of CHF and either fastest OAVRT cycle length
before antiarrhythmic drugs (P = .374) or age at the time of ablation
(P = .455). Labrador Retrievers were more likely to have biventricular
CHF than non-Labrador breeds (P = .010).
Cardiac medications administered before presentation are listed
in Table 2. Thirty-eight dogs (42.7%) were taking 1-2 medications,
whereas 51 dogs (57.3%) were receiving ≥3 medications. Only minor
CBC and serum biochemical profile abnormalities were found, the
most common being a mild increase in ALT activity (9/89 dogs).
3.3 | Electrographic findings
Narrow complex tachyarrhythmias were seen in all dogs (Table 3).
Two dogs initially presented to veterinarians with wide complex
tachyarrhythmias thought to be ventricular tachycardia (VT). Both
wide complex tachyarrhythmias became narrow complex tachyar-
rhythmias as IV treatment resulted in mild rate slowing and resolution
of prior intraventricular conduction delay. In 4 other dogs, the initial
3-5 complexes of OAVRT were wide complex because of right bundle
branch block, which resolved with continuation of the tachycardia.
Median documented tachycardia cycle length before antiarrhythmic
medications was 180 ms (range, 140-240 ms), corresponding to heart
rates between 250 and 428 bpm. No significant difference was found
between OAVRT cycle length of Labrador Retrievers and other breeds
(P = .645). P0 waves (confirmed retrograde AP conduction at EPS)
could be identified within the ST segment or T wave during tachycar-
dia in at least 1 surface ECG lead of 87/89 dogs with a median RP’
interval of 80  11 ms (Figure 3A). P0 waves within the ST segment or
T wave of sinus complexes occurred intermittently in 70/89 dogs,
having a fixed RP0 interval equal to RP0 measured during OAVRT
TABLE 2 Medications administered prior to RFCA
Medication No. of cases
Median dosage
mg/kg/day (range)
Diltiazem 67 4.19 (2.00-12.12)
Sotalol 55 3.76 (1.86-9.53)
Enalapril 27 0.80 (0.22-1.49)
Furosemide 26 3.06 (0.96-5.32)
Pimobendan 24 0.53 ((0.30-0.78)
Procainamide 24 52.44 (30.1-96.62)
Digoxin 19 0.009 (0.006-0.020)
Mexiletine 12 18.22 (15-20.93)
Atenolol 6 1.08 (0.72-2.44)
Propafenone 5 23.36 (9.91-25.28)
Benazepril 5 0.71 (0.28-0.95)
Spironolactone 3 2.39 (2.23-2.54)
Amiodarone 2 11.38 (7.54-15.23)
Verapamil 2 4.99 (3.05-6.92)
Propranolol 2 1.95 (1.95-1.95)
Doxycycline 2 9.25 (8.47-10.07)
L-carnitine 1 81.6 (81.6-81.6)
Taurine 1 40.8 (40.8-40.8)
Flecainide 1 5.0 (5.0-5.0)
Prednisone 1 0.30 (0.30-0.30)
TABLE 3 Electrocardiographic and electrophysiologic data from
89 dogs with accessory atrioventricular pathways
OAVRT measurements
Mean  SD or median
(range) P value
OAVRT cycle length (HR)
prior to medication
180 ms (140-240 ms)* *<.0001
OAVRT cycle length during
EPS
219 ms (146-290 ms)*
Surface ECG RP0 interval
during OAVRT prior to EPS
77.6  9.4 ms** **.0033
Surface ECG RP0 interval
during OAVRT at EPS
75.7  8.2 ms**
Surface ECG P0R interval
during OAVRT prior to EPS
107  19 ms*** ***<.0001
Surface ECG P0R interval
during OAVRT at EPS
141  22 ms***
VA interval to distal ablation
dipole at site of success
51 ms (32-80 ms)
Shortest VA interval to
standard catheter dipole
61.5  15.5 ms
Shortest cycle length at which
retrograde AP conducts 1:1
during decremental RV
pacing
190 ms (150-290 ms)
AH in OAVRT 112 ms (48-206 ms)^ <^.0001
AH in sinus rhythm 70 ms (40-125 ms)^
HV in OAVRT 34.5 ms (24-49 ms)# #<0.0001
HV in sinus rhythm (includes
ventricular preexcitation)
31 ms (−26 to 49 ms)#
Ventricular preexcitation
measurements
PR interval on preexcited
complexes prior to EPS
60 ms (40-90 ms)## ##0.7058
PR interval on preexcited
complexes at EPS
60  15 ms##
PR interval on nonpreexcited
complexes prior to EPS
110 ms (80-140 ms)
Shortest cycle length at which
antegrade AP conducts 1:1
during decremental HRA
pacing
303.6  127.5 ms
Antegrade AP effective
refractory period
243.1  65.0 ms
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(Figure 3B). P0 waves generally were visualized best in the caudal
(inferior) limb leads (II, aVF, or III), but in 18% of dogs, the cranial
(superior) limb leads provided the best visualization of the P0 onset.
Forty-three of 89 dogs (48.3%) exhibited VPE sometime during
sinus rhythm. Twenty-three of these dogs had manifest VPE, whereas
20 had intermittent VPE (Figure 3C). Ventricular preexcitation was
seen only on pre-ablation Holter monitoring but not on baseline ECGs
in 2 dogs. Median preexcited PR interval was 59 ms (range, 40-90 ms),
whereas the median PR interval on nonpreexcited complexes was
110 ms (range, 80-140 ms). Median QRS duration during VPE was
80 ms (range, 55-120 ms). Fourteen dogs had preexcited PR intervals
≥60 ms, and 10 dogs had preexcited QRS durations ≤60 ms. Labrador
retrievers exhibited VPE significantly less frequently (12/42 or 28.5%
of Labradors) than did non-Labradors (31/47 or 66.0% of other
breeds, P = .001).
Other arrhythmias were noted before ablation in 53/89 dogs.
These included single ventricular premature complexes (VPCs, 36/89),
ventricular triplets or nonsustained VT (16/89), single atrial premature
complexes (APCs, 17/89), paroxysmal AF (6/89), and asystole requir-
ing resuscitation (2/89).
FIGURE 3
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3.4 | Echocardiographic findings at presentation
Echocardiographic measurements are shown in Table 4. Left ventricu-
lar diastolic chamber dilatation (LVIDdN >1.73) at presentation was
seen in 31/89 dogs, whereas 30/89 dogs had LA dilatation (2D RPS
SAX LA:Ao > 1.5, all of which also had LV dilatation). Subjective right
atrial dilatation (20/89 dogs) and right ventricular dilatiaton (16/89
dogs) were seen less frequently. Forty-one of 89 dogs (46.1%) met cri-
teria for LV systolic dysfunction. No relationship was found between
presence of systolic dysfunction and fastest OAVRT cycle length
before antiarrhythmic drugs (P = .42), time from initial diagnosis (P =
.87), or age at time of ablation (P = .08). Labrador Retrievers were not
more likely to have systolic dysfunction than non-Labrador breeds
(P = 0.368). Mitral regurgitation was trace to mild in 44/89 dogs and
moderate to severe in 20/89 dogs. Tricuspid regurgitation was trace
to mild in 53/89 dogs and moderate to severe 17/89 dogs. Congenital
or acquired (other than TICM) structural heart disease occurred in
12/89 dogs and included tricuspid dysplasia (5/89), mitral dysplasia
(2/89), mitral and tricuspid valve endocardiosis (3/89), patent ductus
arteriosus (1/89), and subaortic stenosis (1/89).
3.5 | Electrophysiologic study
Ninety-six APs were identified in the 87 dogs completing the mapping
procedure (Table 3). Nine dogs (10.3%) had 2 APs, whereas 78 dogs
(89.7%) had a single AP. Four of 41 Labrador Retrievers (9.8%) had
2 APs, whereas 5 of 46 non-Labradors (10.9%) had 2 APs (P = 1.00).
Median OAVRT cycle length during EPS was 219 ms (range, 146-290
ms), significantly longer than that recorded in the awake state (P <
0.0001). The majority of this prolongation came from an increased P0R
interval (Table 3), rather than R0P interval, although both were pro-
longed in the anesthetized state. Incessant OAVRT in many dogs
necessitated IV use of antiarrhythmic agents (diltiazem or lidocaine)
the night before or morning of RFCA, with potential effects on tachy-
cardia cycle length. Rapid retrograde AP conduction properties were
uniformly noted with 1:1 retrograde VA conduction at pacing cycle
lengths <200 ms in 73/89 dogs. Only 1 AP had decremental retro-
grade conduction properties.
Antegrade AP conduction occurred during sinus rhythm or atrial
pacing in 42/96 APs (43.8%) and typically was less robust than retro-
grade conduction. Only 5 APs conducted antegradely 1:1 at pacing
cycle lengths <200 ms (mean for all antegrade APs, 303  127.5
msec). All but 1 AP that conducted antegradely also conducted retro-
gradely. Accessory pathways exhibiting manifest VPE conducted 1:1
in the antegrade direction at significantly faster atrial pacing cycle
lengths (median, 240 ms) than APs showing intermittent VPE (median,
450 ms; P = .0003). Labrador Retrievers were significantly less likely
than other breeds to have an AP capable of antegrade conduction
(12/41 versus 30/46; P = .001).
FIGURE 3 A, Surface ECG leads and intracardiac electrograms demonstrating retrograde accessory pathway activation during orthodromic
atrioventricular reciprocating tachycardia. The figure on the left displays 9 of the 12 ECG leads recorded in the awake state just prior to
electrophysiologic study. A narrow complex tachycardia at a cycle length of 221 ms is present. Arrows point to representative retrograde P0
waves visible within the early ST segment following each QRS complex. Paper speed 50 mm/s, calibration 10 mm/mV. The figure on the right is
at the time of electrophysiologic study. Three surface ECG leads and eight intracardiac dipole recordings are shown. Orthodromic atrioventricular
tachycardia is present. Electrograms are labeled as follows: A0, retrograde atrial depolarization over the accessory pathway; V, ventricular
depolarization; H, His bundle activation. The earliest retrograde atrial activation is seen in the proximal coronary sinus for this right posterolateral
free wall accessory pathway. Sweep speed is 100 mm/s. B, Surface ECG leads and intracardiac electrograms demonstrating intermittent
retrograde accessory pathway conduction during sinus rhythm. The figure on the left is a baseline ECG during sinus rhythm in the awaken state.
Note that the second and fifth sinus complexes have a deflection within the ST segment (arrows) that is not present on the first, third, and fourth
complexes. This deflection represents retrograde accessory pathway conduction of the sinus impulse once it reaches the ventricles. Atrial
depolarization results and is seen as a retrograde P0 wave on the surface ECG. The RP0 interval is always the same. Paper speed 25 mm/s,
calibration 10 mm/mV. The figure on the right is at the time of electrophysiologic study. Three surface ECG leads and nine intracardiac leads are
shown (100 mm/s). The first sinus complex conducts retrograde over a concealed right posteroparaseptal accessory pathway, while the second
sinus complex does not. A, sinus nodal depolarization of the atria; H, His bundle electrograms; V, ventricular depolarization; A0 , retrograde
depolarization of the atria over the accessory pathway. Note that no A0 is visible on the second sinus complex. C, Twelve-lead ECG from a 3-year-
old Boxer with a midseptal accessory pathway at the time of electrophysiologic study (50 mm/s, 10 mm/mV). The first, third, and fifth complexes
of this sinus rhythm have a shorter PR interval, slurred upstroke to the QRS complex, and prolonged QRS duration compared to the second and
fourth complexes. This represents intermittent ventricular preexcitation. Antegrade accessory pathway conduction manifests on the surface ECG
in this dog for every other sinus complex
TABLE 4 Echocardiographic data of 89 dogs with accessory
atrioventricular pathways prior to radiofrequency catheter ablation
Echocardiographic measurement
Mean  SD or median
(range)
LVIDdN 1.64 (1.26-2.3)
LVIDsN 1.18  0.21
LVEF 53  12%
LVESVI 37.8  21.9 ml/M2
LVFS 25% (5%-42.8%)
LA:Ao ratio in 2D right parasternal
short-axis view
1.35 (1.00-2.12)
Mitral regurgitation
None 25
Trace or mild 44
Moderate 15
Severe 5
Tricuspid regurgitation
None 19
Trace or mild 53
Moderate 12
Severe 5
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Accessory pathway location was distributed as shown in Figure 4.
The majority of APs (88/96 or 91.7%) were located along the tricuspid
annulus, with only 8/96 (8.3%) located along the mitral annulus. Only
3 of these 8 left-sided APs required a retrograde aortic approach, but
1 owner declined this approach, precluding detailed AP mapping and
ablation. The other 5 left-sided APs could be ablated from a right-
sided approach within the proximal CS or middle cardiac vein. The
most common AP location was right posteroparaseptal (45/96,
46.9%), followed by right free wall (36/96, 37.5%). Rapid termination
of AP conduction, as shown in Figure 5, was noted at the successful
ablation site. Ventricular-to-atrial timing to the distal ablation catheter
bipole at the site of success was 51 ms (range, 32-80 ms). Time to AP
block from RF onset was 3.8 seconds (range, 1.2-8.5 seconds).
Twenty-four dogs had retrograde AV nodal conduction after suc-
cessful AP ablation, whereas complete VA block during RV pacing was
noted in the remaining 61 dogs having successful ablation of all APs.
Ventricular-to-atrial intervals over the retrograde AV node had a
median of 134 ms (range, 72-205 ms), 83 ms (range, 40-125 ms) lon-
ger than those seen with retrograde APs.
Other arrhythmias encountered during EPS included nonsus-
tained AF (14/89), sustained AF requiring synchronized cardioversion
(2/89), automatic right atrial tachycardia (3/89), automatic left atrial
tachycardia (1/89), complete AV block requiring pacemaker implanta-
tion (1/89), VF (3/89; which quickly followed preexcited AF in 2 of
these 3 dogs), and electromechanical dissociation (1/89). Dual
FIGURE 4 Diagram corresponding to a left anterior oblique
fluoroscopic view showing the mitral and tricuspid valve annuli
(11, 24). The number of accessory pathways found in this group of
89 dogs at each location is marked. RPS, right posteroparaseptal; LPS,
left posteroparaseptal; SPS, superoparaseptal or anteroparaseptal; AV,
atrioventricular. The location of the AV node is marked by the
symbol **
FIGURE 5 Three surface ECG leads and eight intracardiac dipoles are displayed during radiofrequency catheter ablation (sweep speed
100 mm/s). The first 5 complexes represent orthodromic atrioventricular reciprocating tachycardia with retrograde atrial activation (labeled as A0
in the fifth complex) over a right posteroparaseptal accessory pathway. Earliest retrograde atrial activation in these standard leads occurs in the
CS 9, 10 dipole. With the sixth complex, the accessory pathway is successfully ablated, as ventricular activation (V) is not followed by retrograde
atrial activation. In this dog, OAVRT terminates 3.4 s after the onset of radiofrequency energy (RF onset is not shown in this figure), and sinus
rhythm resumes after a ventricular complex. Small His bundle electrograms are marked with H. Sinus nodal activation of the atria is labeled A
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antegrade AV nodal pathways were identified post-ablation in 3/89
dogs, whereas dual retrograde AV nodal pathways were present in
2/89 dogs. Four dogs had single atypical AV nodal echoes during ven-
tricular extrastimulus pacing (VA conduction over the retrograde slow
pathway followed by antegrade conduction over the fast pathway).
No dog had inducible AV nodal reentrant tachycardia.
3.6 | Procedural and long-term outcomes
Eighty-six dogs survived EPS/RFCA. Three dogs died during induction
of general anesthesia or EPS. Two of these dogs developed VF,
whereas the third (with the most severe myocardial dysfunction)
developed electromechanical dissociation. A fourth dog developed VF
during the procedure, but was resuscitated. Persistent, profound neu-
rologic deficits 5 days postprocedure led to this patient’s euthanasia.
All these cases occurred earlier in the study period. The remaining
85 dogs were followed until time of death, loss to follow-up, or writ-
ing of this article.
Ninety-four APs were ablated. One dog died before ablation of
its right posteroparaseptal AP (due to electromechanical dissociation),
and the owner of the smallest study patient declined detailed mapping
of a left-sided AP via a retrograde aortic approach. Recurrence of AP
conduction occurred in 3 dogs; 2 were early in this study (1999) when
an intraoperative hour-long waiting period after acute disruption of
AP conduction was not followed. These 2 dogs had recurrence within
the first month, whereas the third dog had recurrence 3 months after
the first ablation. Repeat RFCA was successful long-term in all 3 dogs.
Holter monitoring confirmed absence of any evidence of antegrade
(VPE) or retrograde AP conduction (AP echoes or OAVRT) in 76 of
77 dogs, in which it was performed after their last EPS. Retrograde AP
conduction remained in the French bulldog with a left-sided AP that
was not ablated. Other arrhythmias found on the 1-month follow-up
Holter monitoring included: single APCs (>30/24 hours) in 5 dogs,
atrial tachycardia in 4 dogs (all also had single APCs), VPCS
(>30/24 hours) in 9 dogs, ventricular couplets in 1 dog (also having
single VPCs), and nonsustained VT in 2 dogs. The dog that developed
complete AV block during the study with subsequent pacemaker
placement had a ventricular paced rhythm throughout the Holter
monitoring period. All dogs with atrial or ventricular tachyarrhythmias
documented on the 1-month post-RFCA Holter tracing also had evi-
dence of these arrhythmias before ablation. Three additional dogs
developed VT 6 months to 2 years after ablation. One of these was an
English Bulldog that developed arrhythmogenic RV cardiomyopathy,
and the other 2 were active hunting dogs, in which myocarditis was
suspected. Follow-up Holter data were not available for 8 of the
85 dogs. These 8 dogs were treated earlier in the study period and
were followed until death. None of these 8 dogs died because of car-
diac causes. Long-term success rate of a single RFCA procedure in
dogs surviving to ablation was 95%. Overall long-term success rate
when including dogs undergoing a successful second RFCA procedure
was 98.8%.
Of the 41 dogs that met systolic dysfunction criteria before
RFCA, follow-up echocardiograms were available in 29. Significant
improvement in systolic function 1-month post-RFCA was documen-
ted. The most commonly measured LV function values on post-RFCA
echocardiograms performed by referring cardiologists were LVFS and
LVIDsN. The mean increase in LVFS 1 month after RFCA was 12.9%
(pre- versus post-LVFS, P < .0001), whereas the mean decrease in
LVIDsN was 0.31 (pre- versus post-LVIDsN, P = .0001).
Of the 85 dogs surviving >5 days post-RFCA, 45 were confirmed
alive at the time of manuscript preparation, a mean of 4.0  3.2 years
after RFCA. These owners have reported resolution of their dogs’ pre-
senting clinical signs after RFCA. Three dogs are receiving antiarrhyth-
mic agents for ventricular tachyarrhythmias noted on Holter
monitoring. One of these dogs had ventricular tachyarrhythmias docu-
mented before RFCA; the other 2 developed them 6 months to 2 years
after ablation. Two dogs are receiving antiarrhythmic drugs for atrial
tachyarrhythmias documented before ablation. Both of these were
older dogs (8 and 9.7 years) with moderate mitral valve endocardiosis
at presentation for RFCA. Thirty-four dogs have died (11) or were
euthanized (23). The median age at time of death in these dogs was
11.3 years (range, 2.83-15 years), with median time from RFCA of
8.0 years (range, 1.2-13.3 years). Two deaths were cardiac-related;
32 were not (Table 5). The 2 cardiac-related deaths occurred in
1 Boxer and 1 English Bulldog, both with documented ARVC, that
died suddenly 5 years and 4 years after RFCA, respectively. Six dogs
were lost to follow-up (1 between 1 and 2 years post-RFCA,
3 between 2 and 4 years post, and 2 between 7 and 10 years post).
4 | DISCUSSION
Ours is the largest study of APs in dogs to date. Several novel findings
could aid in the identification and treatment of this often elusive con-
dition. The first is confirmation of predisposition of Labrador
Retrievers to APs. Representing nearly half (47%) of dogs presented
for RFCA of APs, Labrador Retrievers appear overrepresented in this
TABLE 5 Causes of death or euthanasia in dogs with
atrioventricular pathways undergoing radiofrequency catheter
ablation
Cause of death/euthanasia
Number
of dogs
Neoplasia 18
Progressive neurologic dysfunction 5
Ventricular fibrillation at time of study 3
Sudden cardiac death related to arrhythmogenic right
ventricular dysplasia
2
Electromechanical dissociation at time of study 1
Acute necrotizing pancreatitis 1
Hepatic failure 1
Pneumonia 1
Laryngeal collapse 1
Gunshot wound 1
Aggression 1
Progressive lower airway disease 1
Progressive gastrointestinal signs thought to be neoplastic
in origin (owner declined advanced diagnostics)
1
Marked polyuria/polydipsia and weight loss (owner
declined advanced diagnostics)
1
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population. Although the most popular breed in the United States,
Labrador Retrievers represent only 15% of all registered dogs accord-
ing to American Kennel Club statistics, falling well short of the per-
centage found in our study.
A male predominance also was found in our study, with Labrador
Retrievers more likely than non-Labrador breeds to be male. In a prior
European case series of 10 dogs, 6 were Labrador Retrievers and all
were male.11 Other case reports include Labrador Retrievers (2),
Boxers (2), Bulldogs (2), Alaskan Malamute (1), Beagle (1), and Golden
Retriever (1).7–10,12,13 Seven of the 9 dogs in these small studies were
male. The possibility of a sex-linked or sex-modified mode of inheri-
tance for APs in Labrador Retrievers can be postulated. Conflicting
reports of male predominance have been reported in studies of
humans with APs.27–33
The prevalence of gastrointestinal signs as the manifestation of
tachycardia in these often young, large breed dogs is important to
note, as many initially were misdiagnosed with dietary indiscretion or
potential gastrointestinal foreign bodies. The common occurrence of
inappetence and vomiting in these dogs should prompt veterinarians
to add OAVRT (or another tachyarrhythmia) to their differential diag-
nostic list for this presentation. If tachycardia is auscultated at presen-
tation, then an ECG should be performed, rather than assuming sinus
tachycardia in response to dehydration or discomfort. If tachycardia is
not detected at presentation, an intermittent tachyarrhythmia still
should be considered, particularly if no other cause is found on rou-
tine diagnostic testing. In this setting, Holter or event monitoring
would be useful.
Surface ECGs can provide useful clues to the presence of an
AP. The rate of OAVRT in dogs not on antiarrhythmic drugs is rapid,
(median, 333 bpm; range, 250-428 bpm) in our study. The OAVRT
rate under general anesthesia was significantly slower, (median,
274 bpm; range, 207-411 bpm). Whether evaluating the awake or
anesthetized OAVRT rates in our study, they are faster than in a previ-
ously reported group of 14 dogs, in which the anesthetized OAVRT
rate was 229  42 bpm.34 Whereas focal atrial tachycardias (FAT) had
faster ventricular rates than OAVRT in that study, median OAVRT rate
in our awake dogs was substantially higher and median OAVRT rate in
our anesthetized dogs was the same as the anesthetized mean FAT
ventricular rate (278 bpm) in the prior study. Isoflurane can affect AV
conduction as well as atrial, ventricular, and AP refractory
periods.35–37 Significant prolongation of the P0R interval and lesser
prolongation of the R0P interval in the anesthetized state versus the
unmedicated, awake state (Table 3) was seen in our group of dogs.
This finding would suggest a greater effect of general anesthesia on
the AV nodal conduction system as compared to the
AP. Hemodynamically compromising, incessant OAVRT in many dogs
not receiving PO antiarrhythmic drugs necessitated conversion with
IV diltiazem (less commonly lidocaine) the night before anesthesia.
Lingering drug effects also may have played a role in slower tachycar-
dia cycle lengths and longer P0R intervals.
Retrograde P0 waves could be seen within the ST segment of
98.8% of dogs on a 6- or 12-lead ECG, representing retrograde con-
duction over the AP and resulting in a short RP’ interval of
80  11 ms. This is similar to the RP’ interval of 85  16.8 ms and the
frequency of identifiable P0 waves in OAVRT reported in another
study.34 Intermittent P0 waves in the ST segments of sinus complexes
were seen in the majority of dogs (78.7%) as well. Retrograde P0
waves, however, often were identifiable only in certain leads, and thus
the more leads recorded, the better the chance of identification. Also,
identification of retrograde P0 waves following a sinus QRS complex
was enhanced with Holter monitoring or extended multiple lead ECG
recordings. Occurrence of wide complex tachycardia does not elimi-
nate the possibility of OAVRT, as 2 dogs had sustained OAVRT with
right bundle branch block. The mimicking of VT by OAVRT conducted
with aberrancy has been reported previously in 1 dog.12
Several dogs in our study experienced paroxysmal AF before or at
the time of EPS or both. A higher occurrence of AF in people with
APs has been reported, particularly in males and in those with mani-
fest APs.38,39 Neither of these predilections was found in our dogs
with AF. Right-sided APs and shorter OAVRT cycle lengths in children
are associated with degeneration of OAVRT into AF and a higher risk
of sudden death.40 Our dogs had predominantly right-sided APs and
short OAVRT cycle lengths, potentially predisposing them to AF.
The distinct predominance of right-sided APs in these dogs coin-
cides with prior smaller studies.7–13 Right posteroparaseptal was the
most common location, followed by right free wall. This distribution is
distinctly different than reported in humans, where ~60% of APs are
left free wall, 25% are septal pathways, and 15% are right free wall
pathways.1 Multiple APs were identified in 10% of dogs in our study,
similar to the 3%-13% of human AP patients with multiple APs.41–50
Five of 19 (26.3%) previously reported dogs with APs had multiple
pathways.7–13 This percentage is higher than observed in our case
series or in larger studies of humans. A large retrospective study of
1088 pediatric AP patients found that congenital heart disease
increased the risk of multiple APs threefold from 8% to 26% in that
population.51 Only 1 of the 9 dogs (11.1%) with congenital heart dis-
ease in our study had multiple APs.
Antegrade conduction over the AP during sinus rhythm or atrial
pacing (VPE) in dogs of our study occurred less frequently than
reported in humans. Antegrade AP conduction was documented in
43.8% of our dogs. This percentage is compared to 64% in a large
study of children and 63%-83% in human adults.51,52 Ventricular pre-
excitation often is more subtle on a surface ECG in dogs than in
humans. Thirty-three percent of VPE dogs in our series had preexcited
PR intervals of 60-90 ms, which is within commonly cited normal ref-
erence ranges.53 Considering Labrador Retrievers alone, occurrence
of antegrade AP conduction decreases to 29.2%. Concealed APs are
more challenging to diagnose. Manifest or intermittent antegrade AP
conduction will point to an AP0s presence during sinus rhythm (VPE),
whereas concealed APs are silent on the surface ECG unless the dog
is in OAVRT or retrograde AP echoes occur during sinus rhythm. The
predominance of Labrador Retrievers and their tendency to have con-
cealed APs poses a diagnostic challenge. Clinicians should maintain
heightened awareness for APs and pursue extended ECG monitoring,
such as Holter monitors, to detect salvoes of tachycardia or intermit-
tent preexcitation in this breed.
Although supraventricular tachyarrhythmias are thought to be
more benign than ventricular tachyarrhythmias, our study highlights
their potentially lethal nature. Atrial fibrillation can degenerate rapidly
into VF in a dog with rapid antegrade AP conduction. This scenario
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occurred in 2 dogs in our study during EPS. Two other dogs had resus-
citated sudden cardiac death before presentation and 13 experienced
syncope.
Myocardial dysfunction secondary to frequent or sustained
OAVRT (TICM) can lead to CHF and resultant euthanasia or death. Its
unique feature is reversibility of this dysfunction upon control of the
arrhythmia.5,8,54 Most of our knowledge regarding pathophysiologic
and morphologic features of TICM is based on a canine model of rapid
pacing.55 Occurrence of TICM relates both to the rapidity and fre-
quency of a given tachyarrhythmia. The sustained heart rate that trig-
gers TICM is not well established in any species. It may manifest
months to years after onset of the tachyarrhythmia, particularly in
individuals with slower or more intermittent tachyarrhythmias. Experi-
mental dogs and human patients with higher tachyarrhythmia rates
develop TICM earlier.55,56 Time to onset of ventricular dysfunction
also is dependent on other factors, including underlying structural
heart disease and patient age.6 We found no relationship between LV
systolic dysfunction and fastest OAVRT cycle length before antiar-
rhythmic drugs or age at time of ablation. Possible explanations
include the following: (1) We did not analyze the frequency of
OAVRT, an important factor in TICM development. Doing so would
require an implantable loop recorder for accurate assessment in dogs.
(2) Systolic function measurements were made at presentation for
RFCA, when most dogs were already on antiarrhythmic and other car-
diac medications. (3) A larger patient population may be needed to
achieve statistical significance.
Tachycardia-induced cardiomyopathy should be considered in all
patients with a DCM phenotype of unknown origin that have a tachy-
arrhythmia. The dramatic difference in prognosis of TICM treated by
eliminating the tachyarrhythmic substrate versus idiopathic DCM war-
rants diligence to rule out this important underlying cause. Data from
several studies and individual case reports have shown that rhythm
control results in significant improvement of ventricular systolic func-
tion and resolution of clinical signs of CHF.8,54,56–58 Follow-up data in
our study confirm the excellent long-term prognosis for recovery from
CHF and ventricular dysfunction in dogs when the tachyarrhythmia is
eliminated by RFCA. Significant improvement in LV systolic function
was seen on 1-month follow-up echocardiograms and all heart failure
medications were discontinued at that time, apart from 2 dogs that
remained on medications such as pimobendan because of underlying
structural heart disease unrelated to their APs. Interestingly, similar to
some older dogs with PDAs that are successfully corrected, some
TICM dogs had a persistent mild decrease in LVFS postablation. These
same dogs, however, still had resolved CHF and improved LA and LV
dimensions. Systolic function measurements did not deteriorate when
pimobendan was discontinued.
Finally, our study confirms the efficacy of RFCA for eliminating
APs, thus curing dogs of associated tachyarrhythmias and often totally
reversing myocardial dysfunction. The long-term success rate of a sin-
gle RFCA in the dogs undergoing ablation was 95% (91% success rate
when including dogs dying before AP ablation). Overall long-term suc-
cess rate when including dogs undergoing successful second RFCA
procedures was 98.8% (95% when including dogs dying before AP
ablation). American Heart Association and American College of Cardi-
ology clinical practice guidelines currently recommend RFCA as first-
line therapy in AP patients with AVRT, preexcited AF, or both, citing
several large case series that support this approach.59 These series
report success rates of 93% to 95% and 3% risk of major complications
in patients followed for 6 months to 8 years.45,46,60–69 Successful RFCA
eliminates the need for continued antiarrhythmic drug therapy (unless
other arrhythmia substrates are present), repeated hospitalizations for
tachyarrhythmia breakthrough or CHF, and lifelong follow-ups with a
veterinary specialist. Given the expense associated with these factors,
an RFCA procedure is economically beneficial as well.
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